BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EVENT HORIZON III who wrote (402)	3/4/2003 7:23:48 PM
From: Arthur Radley	Read Replies (2) of 423

Currently, my favorite biotech is VERS. The CEO spoke today at the Lehman Bros. conference and within minutes of his presentation the stock spiked up on flurry of trades. Why I like VERS is for the following reasons: 1) Just concluded merger with their Italian alliance partner, giving VERS complete control of two drugs in Phase III trials and another drug being developed by GENE that is in Phase III testing. 2) Excellent alliance partnerships with Novartis, etc. 3) Excellent cash position 4) Phase III results for first drug coming this month and NDA planned for April. VERS plans to market the injectable drug in-house and partner the anti-fungal drug due to need for larger sales team. The injectable drug would provide the following: For each $100M in sales, they will bring to the bottom line $35M. The total market for this drug is about $3B. The total worldwide market for their two drugs is about $6B. Would highly suggest anyone taking about 20 minutes and visit the Versicor website and listen to the CEO's presentation this morning.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next